Literature DB >> 2951271

Cyclosporin A enhances streptozocin-induced diabetes in CD-1 mice.

R Iwakiri, S Nagafuchi, E Kounoue, S Nakano, T Koga, M Nakayama, M Nakamura, Y Niho.   

Abstract

Cyclosporin A (CYA), when administered to CD-1 mice treated with a subdiabetogenic dose of Streptozocin (STZ), exacerbated the STZ-induced insulitis and elevated the plasma glucose levels, parallel to a reduction of the insulin content of the pancreas. The possible mechanisms of CYA-mediated aggravation of STZ-induced diabetes are discussed.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2951271     DOI： 10.1007/bf01945570

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  13 in total

1.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

2.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

3.  Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats.

Authors:  U Helmchen; W E Schmidt; E G Siegel; W Creutzfeldt
Journal:  Diabetologia       Date:  1984-09       Impact factor: 10.122

4.  Long-term effects of cyclosporin A on cultured mouse pancreatic islets.

Authors:  A Andersson; H Borg; A Hallberg; C Hellerström; S Sandler; A Schnell
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

5.  Islet-cell-surface antibodies in juvenile diabetes mellitus.

Authors:  A Lernmark; Z R Freedman; C Hofmann; A H Rubenstein; D F Steiner; R L Jackson; R J Winter; H S Traisman
Journal:  N Engl J Med       Date:  1978-08-24       Impact factor: 91.245

6.  Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell.

Authors:  G A Dos Reis; E M Shevach
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

Authors:  C R Stiller; J Dupré; M Gent; M R Jenner; P A Keown; A Laupacis; R Martell; N W Rodger; B von Graffenried; B M Wolfe
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

Review 8.  Cyclosporine: the agent and its actions.

Authors:  B D Kahan
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

9.  Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes.

Authors:  S G Paik; N Fleischer; S I Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

10.  Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.

Authors:  R Assan; G Feutren; M Debray-Sachs; M C Quiniou-Debrie; C Laborie; G Thomas; L Chatenoud; J F Bach
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321
View more
  4 in total

Review 1.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in naive and cyclosporin-treated low-responder murine strains.

Authors:  J R Wright; R B Fraser; S Kapoor; H W Cook
Journal:  Acta Diabetol       Date:  1995-06       Impact factor: 4.280

Review 4.  Role of nutritional factors at the early life stages in the pathogenesis and clinical course of type 1 diabetes.

Authors:  Yukiko Kagohashi; Hiroki Otani
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.